Labcorp Perspectives: Oncology

In this insightful episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with Dr. Mark Sausen, Labcorp's Head of Technology and Innovation, to break down a cutting-edge Phase II clinical trial exploring perioperative immunotherapy for resectable diffuse pleural mesothelioma, a rare and aggressive cancer.Hear firsthand how the introduction of immune checkpoint blockade and an ultrasensitive tumor-informed ctDNA platform offers new hope for tracking and treating patients when imaging falls short. Dr. Sausen shares the technological breakthroughs behind molecular residual disease detection, the impact of ctDNA on progression-free survival, and practical challenges in implementing these assays across multicenter studies.Whether you’re a clinician, researcher, or patient advocate, discover how molecular monitoring is changing the game for mesothelioma and rare cancers alike.Tune in now to reimagine the future of oncology care.Follow UsLinkedIn @labcorpX @labcorpFacebook @labcorpInstagram @labcorpYouTube @LabCorpMediaPresented by Labcorp Oncologywww.oncology.labcorp.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs connects with Suzanne Garner, Senior Director of Strategic Partnerships at Outcomes4Me, to spotlight her remarkable journey as a breast cancer patient, advocate, and now leader in digital health. Suzanne shares her personal story, from an unexpected diagnosis and navigating overwhelming choices, to the pivotal discovery that empowered her to actively participate in her treatment decisions.Together, they discuss the critical role of biomarker and genetic testing in shaping individualized treatment plans and the impact of patient-friendly technology, like the Outcomes4Me app, in driving health equity and expanding access to clinical trials. Learn how education, self-advocacy, and digital tools are changing the cancer care landscape, and why the partnership between patient and oncologist matters more than ever.Tune in for hope, practical insights, and real-world tools for patients, providers, and caregivers alike.Follow UsLinkedIn @labcorpX @labcorpFacebook @labcorpInstagram @labcorpYouTube @LabCorpMediaPresented by Labcorp Oncologywww.oncology.labcorp.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with colleague and pathologist Dr. Kyle Strickland to explore the complexities of ovarian cancer and the evolving science shaping its diagnosis and treatment.Together, they discuss how ovarian cancer is often misunderstood as a single disease, the importance of accurately classifying its subtypes, and the critical role biomarkers like HRD and RB1 play in improving outcomes. Dr. Strickland shares his latest research on RB1, explains how HRD testing is reshaping patient care, and highlights Labcorp’s advancements with OmniSeq Insight, designed to provide clinicians with deeper insights into tumor biology. Listeners will gain a clearer understanding of how these scientific developments are transforming precision oncology and opening the door to new possibilities for ovarian cancer patients.Tune in to the full conversation now.Follow UsLinkedIn @labcorpX @labcorpFacebook @labcorpInstagram @labcorpYouTube @LabCorpMediaPresented by Labcorp Oncologywww.oncology.labcorp.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Real Story of Hope, Testing, and Targeted Care.In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs speaks with Ken Schlosser about how biomarker testing informed his care plan after a stage IV lung cancer diagnosis in 2019.Ken shares how a routine trip to the ER led to the discovery of an ALK+ alteration, and how comprehensive genomic profiling through OmniSeq helped guide a treatment path that has kept him thriving for more than six years.They also discuss the role of patient education and advocacy in expanding access to precision testing, as well as why understanding your biomarker status can make a significant difference in care outcomes.This episode offers an inspiring look at how data-driven decisions can transform lives and why testing is crucial from the outset.Listen to the full conversation now.Follow UsLinkedIn @labcorpX @labcorpFacebook @labcorpInstagram @labcorpYouTube @LabCorpMediaPresented by Labcorp Oncologywww.oncology.labcorp.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Precision oncology is evolving fast, and staying ahead means rethinking how we test, monitor, and treat cancer.In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs sits down with Dr. Michelle Green, senior manager of oncology genomics, to talk about the major highlights from the ASCO Annual Meeting.They explore Labcorp’s HER2 expression study in breast cancer, which found significant changes in HER2 status over time, and what that means for retesting and clinical decisions. Michelle and Rebecca also discuss new data on HER3-targeting antibody-drug conjugates, including the potential for treating both breast and lung cancers, and advances in ctDNA testing across tumor types.From molecular profiling to liquid biopsy, this episode provides a wide-ranging look at how new tools and emerging biomarkers are shaping the future of personalized oncology care.Listen to the full conversation now.Follow UsLinkedIn @labcorpX @labcorpFacebook @labcorpInstagram @labcorpYouTube @LabCorpMediaPresented by Labcorp Oncologywww.oncology.labcorp.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tumor biology is rewriting the rules of cancer treatment.In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs talks with Dr. Heidi Ko, Director of Medical Affairs at Labcorp and a breast medical oncologist, about the rapid evolution of tumor-agnostic therapies and HER2-targeted treatment strategies.They unpack what these FDA approvals actually mean in clinical practice, why HER2 is becoming relevant far beyond breast and gastric cancer, and how biomarkers like ERBB2 amplification and HER2 protein expression are shaping decisions across tumor types.Dr. Ko shares her insights from the DESTINY-PanTumor02 trial, discusses why tissue stewardship is more important than ever, and breaks down what oncologists need to know about interpreting HER2 data across IHC, FISH, and NGS.Whether you’re navigating biomarker testing workflows or just trying to keep up with precision oncology’s fast pace, this episode offers timely context and clear clinical takeaways.Tune in now.Follow UsLinkedIn @labcorpX @labcorpFacebook @labcorpInstagram @labcorpYouTube @LabCorpMediaPresented by Labcorp Oncologywww.oncology.labcorp.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Genetic testing is no longer optional — it’s essential.Welcome to the first episode of Labcorp Perspectives: Oncology, where host Dr. Rebecca Previs sits down with Sarah Young, a genetic counselor and Clinical Program Manager for Oncology at Labcorp, to talk about the growing importance of genetic testing in prostate cancer care.Sarah shares insights from the recent American Urological Association (AUA) conference, where she helped lead the first plenary session focused on genetic testing in urologic oncology. Together, they discuss the latest research supporting universal germline testing, the clinical relevance of both germline and somatic testing, and how this information can directly influence treatment decisions, including eligibility for targeted therapies like PARP inhibitors.They also explore barriers to adoption, including provider education gaps, complex guidelines, and limited access to genetics professionals, and offer practical solutions like mainstream testing, digital education tools, and Labcorp’s post-test counseling support.Hear how broader testing strategies are reshaping care pathways, improving outcomes, and helping to close gaps for high-risk and historically underserved patient populations.Tune in now.Follow UsLinkedIn @labcorpX @labcorpFacebook @labcorpInstagram @labcorpYouTube @LabCorpMediaPresented by Labcorp Oncologywww.oncology.labcorp.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Explore the ever-evolving world of cancer care in our insightful content series, Labcorp Perspectives as we delve into the latest advancements in oncology diagnostics and their impact on patient outcomes. Each episode brings together leading oncology experts to discuss:•    Groundbreaking research: Uncovering the cutting-edge science shaping the future of cancer treatment•    Practical applications: Learning how precision medicine translates from lab to the clinic•    Real-world challenges: Exploring the hurdles faced in oncology care and discovering potential solutionsMore than just information, this series fosters collaboration and unbiased education. Labcorp Perspectives not only empowers healthcare professionals and researchers but also patients to stay informed, inspired and at the forefront of medical oncology.